전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved15 programs
CGTStandard DatabasestaleHoffmann-La RochePhase 2

Interferon-Alfa-2b (Interferon-Alfa-2b)

Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface; Malignant Peritoneal Mesothelioma · Adult T-cell Leukemia-Lymphoma

#AdultT-cellLeukemia-Lymphoma#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 88Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Hu5F9-G4 (Magrolimab, Magrolimab (Hu5F9-G4))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#monoclonal-antibody#BladderCancer+2
Trials 35Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Selicrelumab (Selicrelumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#monoclonal-antibody#Hoffmann-La
Trials 13Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Emactuzumab (Emactuzumab)

Cancer · Cancer

#Cancer#Antibody#Phase3#monoclonal-antibody#Hoffmann-La
Trials 7Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#monoclonal-antibody#Hoffmann-La
Trials 4Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Etrolizumab (Etrolizumab)

Ulcerative Colitis · Ulcerative Colitis

#UlcerativeColitis#Antibody#Phase3#monoclonal-antibody#Hoffmann-La
Trials 3Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 1

Vanucizumab (Vanucizumab)

Neoplasms · Neoplasms

#Neoplasms#Antibody#Phase1#monoclonal-antibody#Hoffmann-La
Trials 3Status Active
AntibodyLimited DatastaleHoffmann-La RocheApproved

Daclizumab (Daclizumab)

Type 1 Diabetes Mellitus · Myelodysplastic Syndromes

#MyelodysplasticSyndromes#Antibody#Approved#monoclonal-antibody#Type1DiabetesMellitus+1
Trials 2Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 1

Cibisatamab (Cibisatamab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#monoclonal-antibody#Hoffmann-La
Trials 1Status Discontinued
AntibodyLimited DatastaleHoffmann-La RochePhase 1

RO5323441 + bevacizumab [Avastin] (RO5323441 + bevacizumab [Avastin])

Glioblastoma Multiforme · Glioblastoma Multiforme

#GlioblastomaMultiforme#Antibody#Phase1#monoclonal-antibody#Hoffmann-La
Trials 1Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 1

atezolizumab (Tecentriq, RO7567132 and Atezolizumab)

Cancer-Neoplasms · Cancer-Neoplasms

#Cancer-Neoplasms#Antibody#Phase1#monoclonal-antibody#Hoffmann-La
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
CGTLimited DatastaleJoshua Sasine, MD, PhDPhase 1

autologous hematopoietic stem cells added to planned CAR T (autologous hematopoietic stem cells added to planned CAR T)

Hematologic Malignancy; Large B-cell Lymphoma · Hematologic Malignancy

#HematologicMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting